|
Media Releases |
Financial Reports |
Presen-tations |
|
15.03.2004
|
|
|
|
| Fair Lawn - Lonza Ltd. and Lonza Inc., both subsidiaries of Lonza Group Ltd., are pleased to announce that the U.S. Patent and Trademark Office on March 2, 2004 confirmed the validity of Lonza's U.S. Patent No. 5,073,376 against an attack by an admitted infringer. The subject patent covers enteric preparations (solid oral dosage forms) of L-Carnitine L-Tartrate in tablet, capsule and powdered form, and the making and using of such preparations. |
Validity of L-Carnitine L-Tartrate's US Patent Upheld
|
 |
The Patent Office was presented with an exhaustive compilation of prior art, some of which had not been considered at the time the patent was initially granted, and confirmed that Lonza's invention was patentable. This decision strengthens the presumption of validity of the patent and reinforces Lonza's determination to maintain and enforce its patent rights in the L-Carnitine market.
Lonza is a life sciences driven company, headquartered in Switzerland, which generated sales of CHF 2.24 billion in 2003. It operates 18 production and R&D facilities in eight countries and employs 5660 people worldwide. Lonza is one of the leading custom manufacturers of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries. In addition, Lonza also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds. For more information please visit the company's websites at www.lonza.com or www.carnitine.com.
For further information please contact:
Reto Rieder
Director Nutrition
Lonza Inc.
Tel +1 201 794 2649
Fax +1 201 794 2695
reto.rieder@lonza.com
Christine Casper
Communications Manager
Lonza Inc.
Tel +1 201 794 2448
Fax +1 201 794 2695
christine.casper@lonza.com
|
|
|
